NCT06793189View on ClinicalTrials.gov

MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

145

Participants

Timeline

Start Date

January 21, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Marginal Zone Lymphoma(MZL)
Interventions
DRUG

Obinutuzumab and Orelabrutinib

Induction: Obinutuzumab (1000 mg on days 1, 8, and 15 of cycle 1; 1000 mg on day 1 of cycles 2-6, cycle length=21 days) and Orelabrutinib (150 mg once daily).

DRUG

Obinutuzumab, Orelabrutinib and Lenalidomide

Induction: Obinutuzumab (1000 mg on days 1, 8, and 15 of cycle 1; 1000 mg on day 1 of cycles 2-6, cycle length=21 days), Orelabrutinib (150 mg once daily), and Lenalidomide (25 mg on days 2-11 of cycles 1-6, cycle length=21 days).

DRUG

Orelabrutinib

Maintenance: Orelabrutinib monotherapy (150 mg once daily up to 24 months).

DRUG

Orelabrutinib

Maintenance: Orelabrutinib monotherapy (150 mg once daily up to 24 months).

All Listed Sponsors
lead

Ruijin Hospital

OTHER